Alectinib for advanced ALK-positive, non-small cell lung cancer – first line

NIHR HSRIC
Record ID 32016000369
English
Authors' objectives: Alectinib is intended to be used as first line therapy for the treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer. If licensed, it will provide an additional, oral treatment option for this patient group. Alectinib is a highly selective, next-generation ALK inhibitor with potent in vitro activity against both wild-type ALK and mutated ALK, including mutations that confer resistance to crizotinib. Alectinib does not currently have Marketing Authorisation in the EU for any indication. Non-small cell lung cancer is the most common type of lung cancer, accounting for approximately 85-90% of all lung cancers. Lung cancer is the most common cause of cancer-related death in the UK. In 2011, approximately 31,000 new cases of non-small cell lung cancer were diagnosed in England. ALK-positive disease occurs in around 4-5% of non-small cell lung cancers. Smoking is the main cause of lung cancer, responsible for more than 80% of cases. Treatment for advanced or metastatic non-small cell lung cancer aims to prolong survival, improve quality of life and control disease-related symptoms. First line treatment options include chemotherapy (pemetrexed, gemcitabine, docetaxel, paclitaxel or vinorelbine, alone or in combination with platinum therapy), erlotinib or gefitinib, surgery, photodynamic therapy and brachytherapy. Alectinib is currently in a phase III clinical trial comparing its effect on progression-free survival against treatment with crizotinib.
Details
Project Status: Completed
Year Published: 2015
URL for published report: http://www.hsric.nihr.ac.uk/topics/alectinib-for-advanced-alk-positive-non-small-cell-lung-cancer-first-line/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents
Contact
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.